Omeros Corporation (OMER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Omeros Corporation (OMER) has a cash flow conversion efficiency ratio of -0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.15 Million) by net assets ($-51.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OMER stock market capitalisation for the company's overall valuation and market capitalisation.
Omeros Corporation - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Omeros Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Omeros Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omeros Corporation ranked by their cash flow conversion efficiency. Explore OMER cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CT Real Estate Investment Trust
TO:CRT-UN
|
0.026x |
|
Beijing Bei Mo Gao Ke Friction Mate
SHE:002985
|
0.056x |
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
-0.037x |
|
Rianlon Corp
SHE:300596
|
0.066x |
|
Sansure Biotech Inc
SHG:688289
|
0.008x |
|
NINGBO HENGSHUAI Co. LTD.
SHE:300969
|
0.042x |
|
MPC Container Ships ASA
OL:MPCC
|
0.080x |
|
HYDROGRAPH CLEAN POWER
F:M98
|
-0.100x |
Annual Cash Flow Conversion Efficiency for Omeros Corporation (2007–2025)
The table below shows the annual cash flow conversion efficiency of Omeros Corporation from 2007 to 2025. View OMER stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-121.23 Million | $-116.09 Million | 0.958x | +17.52% |
| 2024-12-31 | $-182.61 Million | $-148.80 Million | 0.815x | +127.24% |
| 2023-12-31 | $-24.98 Million | $74.73 Million | -2.991x | -196.34% |
| 2022-12-31 | $85.68 Million | $-86.48 Million | -1.009x | +78.12% |
| 2021-12-31 | $23.78 Million | $-109.72 Million | -4.614x | -656.68% |
| 2020-12-31 | $-120.75 Million | $-100.09 Million | 0.829x | +50.42% |
| 2019-12-31 | $-109.02 Million | $-60.07 Million | 0.551x | +153.20% |
| 2018-12-31 | $100.16 Million | $-103.74 Million | -1.036x | -108.05% |
| 2017-12-31 | $-2.81 Million | $-36.23 Million | 12.874x | +836.02% |
| 2016-12-31 | $-37.45 Million | $-51.50 Million | 1.375x | -44.67% |
| 2015-12-31 | $-26.23 Million | $-65.21 Million | 2.486x | +82.66% |
| 2014-12-31 | $-42.65 Million | $-58.04 Million | 1.361x | -15.75% |
| 2013-12-31 | $-18.38 Million | $-29.70 Million | 1.615x | +903.15% |
| 2012-12-31 | $-214.58 Million | $-34.55 Million | 0.161x | -96.52% |
| 2011-12-31 | $-5.55 Million | $-25.67 Million | 4.622x | +752.34% |
| 2010-12-31 | $20.47 Million | $-14.50 Million | -0.708x | -60.65% |
| 2009-12-31 | $43.15 Million | $-19.03 Million | -0.441x | -304.36% |
| 2008-12-31 | $-91.17 Million | $-19.67 Million | 0.216x | +5.44% |
| 2007-12-31 | $-69.94 Million | $-14.31 Million | 0.205x | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more